

Canine pyoderma clinical vaccine trial

Purpose of study

The purpose of this study is to test the ability of the new vaccine to stimulate an immune response in dogs with skin infections and to assist their immune systems in destroying the bacteria. Participants should be dogs that have been diagnosed with a bacterial skin infection that is not responding to standard antibiotic treatments.

Eligibility criteria


- Dogs diagnosed with pyoderma.
- Dogs must weigh a minimum of 10 pounds.

Study details

Duration of the study is 4 weeks. The UTCVM Dermatology Service will need to see the patient on days 0, 7, 14, and 28. Owners must be willing to return weekly for appointments to re-administer vaccine and assess response to therapy. The patient will receive a bacterial culture and skin cytology as part of the standard of care for diagnosing the skin infection at no cost to you. Blood will be collected for a CBC and chemistry panel and urine will be obtained for urinalysis to obtain baseline values. The client and primary veterinarian will be provided with these results and the tests and the visits will be at no cost to you.

Study benefits & cost

Office visits, bloodwork and urinalysis will be provided at no cost to the client. Participation in this study will help the future treatment of dogs with pyoderma. Additional costs to the client may be discussed.



Think you have an eligible patient?

Contact Dr. Linda Frank - lfrank@utk.edu | 865-755-8195

Primary Investigator: Dr. Stephen Kania, UTCVM Immunology

Co-Investigators: Dr. Linda Frank, UTCVM Dermatology

This study is IACUC-approved (#2572).

THIS IS A PLACEBO CONTROLLED STUDY.